文献速递冠心病血脂与心血管预防

Evolocumab对需血运重建的复杂冠状动脉病变的影响

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
PubMed 文献 · J Am Coll Cardiol · 2020-11-13

FOURIER试验随机分配27,564例稳定动脉粥样硬化性心血管疾病患者接受evolocumab或安慰剂,随访中位2.2年。Evolocumab使任何冠状动脉血运重建风险降低22%,复杂血运重建风险降低29%,复杂PCI风险降低33%,CABG风险降低24%。

要点

  • Evolocumab降低复杂血运重建风险29%(HR 0.71,95%CI 0.61-0.84)。
  • Evolocumab降低复杂PCI风险33%(HR 0.67,95%CI 0.54-0.84)。
  • Evolocumab降低CABG风险24%(HR 0.76,95%CI 0.60-0.96)。

核心结论

  • 在稳定动脉粥样硬化性心血管疾病患者中,他汀治疗基础上加用evolocumab可显著降低需血运重建的复杂冠状动脉病变风险,包括复杂PCI和CABG。

研究设计与样本

  • FOURIER试验为随机对照试验,纳入27,564例接受他汀治疗的稳定动脉粥样硬化性心血管疾病患者,随机接受evolocumab或安慰剂,中位随访2.2年。
  • 血运重建事件的临床记录经盲法审阅以评估冠状动脉解剖和手术特征。

主要发现

  • 1,724例患者接受冠状动脉血运重建,其中1,482例接受PCI,296例接受CABG,54例两者均接受。
  • 632例(37%)患者接受了复杂血运重建。
  • Evolocumab使任何冠状动脉血运重建风险降低22%(HR 0.78,95%CI 0.71-0.86,p<0.001)。
  • Evolocumab使简单PCI风险降低22%(HR 0.78,95%CI 0.70-0.88,p<0.001),复杂PCI风险降低33%(HR 0.67,95%CI 0.54-0.84,p<0.001),CABG风险降低24%(HR 0.76,95%CI 0.60-0.96,p=0.019),复杂血运重建风险降低29%(HR 0.71,95%CI 0.61-0.84,p<0.001)。
  • Evolocumab对复杂血运重建的风险降低幅度随时间有增加趋势(第1年、第2年和超过2年的风险降低分别为20%、36%和41%)。

关键数值与推荐

  • 复杂PCI定义为多支血管PCI、≥3枚支架、≥3处病变治疗、分叉PCI或总支架长度>60 mm中至少满足1项。
  • 复杂血运重建定义为复杂PCI或CABG的复合终点。

临床怎么用

  • 对于接受他汀治疗的稳定动脉粥样硬化性心血管疾病患者,加用evolocumab可降低需复杂血运重建的冠状动脉病变风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study sought to evaluate the ability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to reduce the risk of complex coronary atherosclerosis requiring revascularization. BACKGROUND: PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall. METHODS: FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) was a randomized trial of the PCSK9 inhibitor evolocumab versus placebo in 27,564 patients with stable atherosclerotic cardiovascular disease on statin therapy followed for a median of 2.2 years. Clinical documentation of revascularization events was blindly reviewed to assess coronary anatomy and procedural characteristics. Complex revascularization was the composite of complex percutaneous coronary intervention (PCI) (as per previous analyses, ≥1 of: multivessel PCI, ≥3 stents, ≥3 lesions treated, bifurcation PCI, or total stent length >60 mm) or coronary artery bypass grafting surgery (CABG). RESULTS: In this study, 1,724 patients underwent coronary revascularization, including 1,482 who underwent PCI, 296 who underwent CABG, and 54 who underwent both. Complex revascularization was performed in 632 (37%) patients. Evolocumab reduced the risk of any coronary revascularization by 22% (hazard ratio [HR]: 0.78; 95% CI: 0.71 to 0.86; p < 0.001), simple PCI by 22% (HR: 0.78; 95% CI: 0.70 to 0.88; p < 0.001), complex PCI by 33% (HR: 0.67; 95% CI: 0.54 to 0.84; p < 0.001), CABG by 24% (HR: 0.76; 95% CI: 0.60 to 0.96; p = 0.019), and complex revascularization by 29% (HR: 0.71; 95% CI: 0.61 to 0.84; p < 0.001). The magnitude of the risk reduction with evolocumab in complex revascularization tended to increase over time (20%, 36%, and 41% risk reductions in the first, second, and beyond second years). CONCLUSIONS: Adding evolocumab to statin therapy significantly reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER); NCT01764633.).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Oyama K, Furtado RHM, Fagundes A, et al. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2020. PMID: 33197560. doi:10.1016/j.jacc.2020.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。